Accretion Nutraveda Limited will hold its 5th Annual General Meeting (AGM) on Thursday, August 27, 2026, via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The meeting, scheduled to begin at 02:00 P.M. IST, is critical for shareholders as they will vote on the appointment of two new independent directors and approve significant remuneration revisions for six existing directors. This governance update follows the company’s strong financial performance in FY26, where it reported a revenue from operations of ₹3,360.31 lakh and a profit after tax of ₹506.83 lakh.

The agenda includes ordinary business items such as the adoption of standalone financial statements for the year ended March 31, 2026, and the re-appointment of Mr. Vivek Ashokkumar Patel, who retires by rotation. Under special business, shareholders are asked to pass resolutions for the appointment of Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale as Non-Executive Independent Directors. Both were initially appointed as Additional Directors by the Board on May 8, 2026, and will serve five-year terms until May 7, 2031.

Remuneration Revisions

A major focus of the AGM is the revision of remuneration for six directors, effective for three years from the 5th AGM to the 8th AGM. The Nomination and Remuneration Committee recommended these changes, citing the need to align compensation with industry standards and individual qualifications. All six directors will be entitled to a monthly salary of up to ₹5,00,000, along with perquisites including group medical insurance, personal accident insurance, and provident fund contributions.

Note: Current remuneration figures represent annual amounts as disclosed in Annexure C. The proposed salary is a monthly cap.

Governance and Compliance

The appointment of Mr. Chand Rameshbhai Kanabar brings expertise in business development and financial strategy, while Ms. Grishma A Shewale contributes over nine years of experience in corporate law and SEBI compliance. The Board stated that their association would benefit the company’s strategic direction. The meeting adheres to MCA Circulars No. 20/2020 and subsequent updates, allowing remote participation without physical presence. Proxies are not permitted for this AGM, though body corporates may appoint authorized representatives.

What the Numbers Show

The remuneration structure highlights a shift towards standardized monthly caps for all executive and non-executive directors, despite varying current annual payouts. For instance, CFO Paraskumar Vinubhai Parmar and WTD Ankurkumar Shantilal Patel currently draw significantly higher annual remuneration (₹13.10 lakh each) compared to the proposed monthly cap of ₹5 lakh (₹60 lakh annually), suggesting the cap allows for additional variable components or incentives not explicitly detailed in the base salary resolution. The company’s FY26 profitability provides a solid foundation for these ongoing governance adjustments.

accretion nutraveda reported a significant acceleration in financial performance for FY26, with revenue from operations jumping 110% year-on-year to ₹3,360.31 lacs. The Ahmedabad-based Contract Development and Manufacturing Organization (CDMO) saw its Net Profit After Tax (PAT) rise 103% to ₹506.83 lacs, reflecting strong execution in the Ayurvedic and nutraceutical segments. This growth trajectory was bolstered by the company’s transition to a publicly listed entity on the BSE SME platform in February 2026.

The filing, submitted under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company's fifth Annual General Meeting scheduled for August 27, 2026. Shareholders will vote on special resolutions regarding the appointment of two independent directors, Chand Rameshbhai Kanabar and Grishma A Shewale, and revisions to the remuneration of six key managerial personnel. The Board also noted that no dividend was recommended for the year, as proceeds are being reinvested into capacity expansion and automation.

Financial Performance

The company’s top-line growth was driven by increased volumes across multiple dosage forms, particularly external preparations and capsules. EBITDA expanded by 88% to ₹700.59 lacs, although the EBITDA margin contracted slightly to 20.85% from 22.79% in the prior year, indicating higher investment in raw materials or production scaling relative to revenue gains.

Earnings Per Share (EPS) stood at ₹9.35 for FY26, compared to ₹6.88 in FY25. The prior year’s EPS has been restated to reflect the bonus issue of 47.88 lakh shares executed in September 2025.

Capital Raises and Liquidity

A pivotal event during FY26 was the successful Initial Public Offering (IPO), which raised ₹24.77 crore through the allotment of 19.20 lakh equity shares at ₹129 per share. The IPO was fully subscribed, with anchor investor allocation completed in January 2026. Additionally, the company completed a rights issue of 45,000 shares at ₹130 each in September 2025, raising ₹58.50 lacs for working capital requirements.

As of March 31, 2026, unutilized IPO proceeds of ₹655.48 lacs were parked in short-term fixed deposits, significantly strengthening the balance sheet. This influx of capital reduced the Debt-Equity ratio sharply from 0.76 in FY25 to 0.12 in FY26. Consequently, the Current Ratio improved dramatically to 11.98 from 2.87, providing ample liquidity for future expansion plans.

Operational Milestones

Accretion Nutraveda continues to leverage its WHO-GMP, AYUSH GMP, and ISO 9001:2015 certified manufacturing facility in Sanand, Gujarat. The company reported an installed capacity of 71.645 million units across tablets, capsules, oral liquids, and oils. Management highlighted that strategic investments in automated machinery are underway to enhance production efficiency and support margin expansion in subsequent quarters.

The workforce grew to 24 employees as of March 2026, up from 17 in the previous year, reflecting hiring in key technical and operational roles. The company maintains a B2B business model, serving both domestic clients and international export markets, with foreign exchange earnings totaling ₹11.04 lacs in FY26.

What the Numbers Show

The divergence between revenue growth (110%) and the slight compression in EBITDA margin (from 22.79% to 20.85%) suggests that Accretion Nutraveda is prioritizing market share expansion and capacity utilization over immediate margin maximization. However, the substantial improvement in liquidity metrics—driven by the IPO—positions the company to absorb higher working capital needs without relying on expensive debt. The sharp decline in Return on Net Worth (from 49.50% to 14.29%) is a mathematical consequence of the massive increase in equity base rather than operational underperformance, a typical pattern post-IPO that should normalize as deployed capital begins generating returns.